8-K: Current report filing
Published on March 30, 2004
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): March 30, 2004
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| Virginia | 001-13467 | 56-1641133 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)
Registrants telephone number, including area code: (804) 648-3820
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
| (a) | Financial statements of businesses acquired. |
N/A
| (b) | Pro forma financial information. |
N/A
| (c) | Exhibits. |
| 99.1 | Press release, dated March 30, 2004, relating to the launch of a new biodefense business initiative. |
2
Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| COMMONWEALTH BIOTECHNOLOGIES, INC. |
||
| By: |
/s/ Robert B. Harris, Ph.D. |
|
| Robert B. Harris, Ph.D. |
||
| President and Chief Executive Officer |
||
Dated: March 30, 2004
3
EXHIBIT INDEX
|
Number |
Description of Exhibit |
|
| 99.1 | Press Release, dated March 30, 2004, relating to the launch of a new biodefense business initiative. |
4